Brian Bizoza, MD, is a Partner on the Pharmaceutical team at Deerfield and provides extensive research and analysis on individual companies operating in the healthcare industry. Brian joined Deerfield in 2012 after seven years as a Portfolio Manager at S Squared Technology, where he was responsible for investments across the healthcare sector.

Read More
Before S Squared, Brian was an analyst at Amaranth Advisors, focused on pharmaceuticals and biotechnology stocks. Prior to Amaranth, Brian started his career in healthcare research as an equity analyst at both Lehman Brothers and Lazard Freres. Brian holds a B.A. in Natural Sciences/Public Health from Johns Hopkins University, and he earned his M.D. from the State University of New York at Syracuse, where he graduated as a member of Alpha Omega Alpha.

Robert Jackson, MD, has been a Partner on the Biotech team at Deerfield since 2001 and the Chief Science Officer since 2014. Bob provides extensive research and analysis on individual companies operating in the healthcare industry. Prior to joining Deerfield, Bob was a healthcare analyst at Janus Capital from 1999 to 2001. Previously, he founded and managed a group ophthalmology practice. Bob earned his undergraduate degree at Rollins College and his medical degree at West Virginia University. He earned an M.B.A. with distinction from the Wharton School at the University of Pennsylvania, was a Cleveland Fellow from Case Western Reserve University, spent a year at

Read More
the Royal Melbourne Hospital in Australia, completed his ophthalmology residency at Case Western Reserve University and was Chief Resident in his final year. Dr. Jackson is also a CFA charterholder.

Joe Pearlberg, M.D., Ph.D., is the Vice President of Scientific Affairs at Deerfield, which he joined in July 2017. Prior to joining Deerfield he was the Vice President of Clinical Development at Infinity Pharmaceuticals from December 2015 until July 2017. Prior to Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi from November 2010 until September 2014. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute.

Read More
Dr. Pearlberg also received his Ph.D. in molecular biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Jorge Aquino is Director of Ventures for Johns Hopkins Technology Ventures (JHTV). He joined JHTV in 2015 to provide leadership and guidance to Johns Hopkins University’s FastForward accelerator program to assist in the development and growth of high value startup companies. Prior to joining Johns Hopkins University Mr. Aquino was with Canon Biomedical, Inc. helping to lead M&A and strategic partnering activities for the lifesciences division of Canon USA, Inc. Previously Mr. Aquino was Senior Manager of Business Development for Emergent BioSolutions Inc. where he was involved in numerous M&A transactions including the acquisition of Trubion Pharmaceuticals and Cangene, Inc.

Read More
Before joining Emergent Mr. Aquino managed the biotech portfolio of Maryland Venture Fund, a division of the Maryland Dept. of Business & Economic Development. Mr. Aquino received his B.S. in Biological Sciences from the University of Maryland, M.S. in Biotechnology from the Johns Hopkins University, and MBA from Loyola University of Maryland.

David Greenwald, Ph.D., currently serves as Director of Corporate Relations for Johns Hopkins Technology Ventures (JHTV). Dr. Greenwald is a founder of Relay Technology Management, Inc. and co-inventor of the Relay Innovation Engine software. Dr. Greenwald was previously Chief Executive Officer of Relay Technology Management and Director of Client Solutions for Decision Resources Group (DRG) after its acquisition of Relay. Dr. Greenwald was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked with the Food and Drug Administration on 510(k) applications for diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute (HHMI) research fellow while earning a B.S. in Cellular Biology and Molecular Genetics

Read More
from the University of Maryland, College Park and was awarded an NIH Ruth L. Kirschstein National Research Service Award (NRSA) towards his Ph.D. research dissertation on gene therapy for Retinitis Pigmentosa, which he completed at Tufts University School of Medicine. Dr. Greenwald lectures on Entrepreneurial Finance and Corporate Finance at The Johns Hopkins Carey Business School, where he is an adjunct faculty.

Barbara Slusher, Ph.D., MAS, is Professor of Neurology (primary), Medicine, Psychiatry, and Neuroscience at Johns Hopkins School of Medicine and the Director of Johns Hopkins Drug Discovery. Dr. Slusher received her undergraduate degree from Dickinson College where she graduated valedictorian, majoring in Chemistry. She received her Ph.D. in Pharmacology and Molecular Sciences from Johns Hopkins School of Medicine while simultaneously earning her Master’s degree in Administrative Science from the Johns Hopkins Carey School of Business (formerly the Hopkins’ School of Continuing Studies). Before joining Johns Hopkins in 2010, Dr. Slusher spent 18 years in the pharmaceutical industry, including several years at the level of Senior Vice President of Research and Translational Development. She has extensive experience in drug discovery through early clinical

Read More
development and was involved in the successful development, launch and/or post marketing support of several branded medicines including Quetiapine (Seroquel TM) for schizophrenia, Palonosetron (Aloxi TM) for chemotherapy-induced nausea and vomiting, Azacytodine (Dacogen TM) for myelodysplastic syndrome, and Fospropofol (Lucedra TM) for monitored anesthesia care (MAC) sedation. At Johns Hopkins, she leads the largest integrated drug discovery program on campus, responsible for translating basic science discoveries at Hopkins into novel small molecule therapeutics. Her veteran drug discovery team consists of medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetic/drug metabolism experts, with an average of 15 years Pharma R&D drug discovery experience. She has also published over 175 scientific articles and is the inventor on 75 issued patents and applications. She co-founded a new biotechnology company in Baltimore called Cerecor and is leading the first-ever International Consortium of over 130 Academic Drug Discovery Centers with over 1500 members in an effort to coordinate and enhance university-led drug discovery efforts.

Bluefield Innovations 2018. All Rights Reserved.